After Benlysta win, HGSI expands cancer pipeline with FivePrime deal
This article was originally published in Scrip
Executive Summary
A week after successfully winning US approval of its lupus drug Benlysta (belimumab), Human Genome Sciences is stepping up its game in the cancer therapy arena by adding a new asset to its development pipeline through a deal with FivePrime Therapeutics, which has licensed the US, Canadian and European Union rights to HGSI for FP-1039, a fibroblast growth factor (FGF) ligand trap under investigation for a variety of cancers (scripintelligence, 10 March 2011).